Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin

Oncology Reports

Volumn 5, Issue 1, 1998, Pages 273-280

  Mantovani, Giovanni ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Acute emesis; Cisplatin, 5 HT3Receptor Antagonists (5 HT3 RA); Delayed emesis; Dexamethasone (D); Granisetron; Head and neck cancer patients; Metoclopramide (M); Ondansetron; Tropisetron

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; GRANISETRON; METOCLOPRAMIDE; NAVELBINE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIEMETICS; CISPLATIN; DEXAMETHASONE; FEMALE; GRANISETRON; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; INJECTIONS, INTRAMUSCULAR; MALE; METOCLOPRAMIDE; MIDDLE AGED; NEOPLASM STAGING; ONDANSETRON; PROSPECTIVE STUDIES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0031965184     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.1.273     Document Type: Article

References (2)

1. Kris MG, Pisters KMW and Hinkley L: Delayed emesis following anticancer chemotherapy. Support Care Cancer 2: 297-300, 1994.
2. Kris MG, Gralla RJ, Clark RA, et al: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3: 1379-1384, 1985.